Jump to: Authorized Access | Attribution | Authorized Requests

Study Description
We performed systematic and comprehensive multi-sector immunogenomic analyses on 93 samples from a cohort of 30 patients with primary or recurrent gliomas or metastatic brain tumors, representing the largest cohort of these brain cancers studied spatially to date. For each patient, we characterized multiple spatially distinct regions using whole-exome (WES), custom capture validation, RNA, and TCR-sequencing. Our findings underscore the significant differences in clonal architecture between gliomas and metastatic brain tumors which translates into distinct neoantigen landscapes and, in turn, tumor infiltrating T cell clonotypic diversity. These data therefore provide high resolution insights into the immunogenomic landscapes within malignant brain tumors which may inform tumor-specific therapeutic approaches.
  • Study Design:
    • Tumor vs. Matched-Normal
  • Study Type:
    • Exome Sequencing
    • Metastasis
    • RNA Sequencing
    • Transcriptome Analysis
    • Tumor vs. Matched-Normal
  • Total number of consented subjects: 30
  • Subject Sample Telemetry Report (SSTR)
Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

All study participants were neurosurgical patients at Barnes-Jewish Hospital with pathologically confirmed stage III/IV glioma or metastatic disease.

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
See articles in PMC citing this study accession
Study Attribution
  • Principal Investigators
    • Gavin Dunn. Washington University, St. Louis, MO, USA.
    • Malachi Griffith. Washington University, St. Louis, MO, USA.